Many treatment guidelines for psoriasis rely heavily on body surface area (BSA) involvement to determine disease severity and eligibility for systemic therapies like biologics. Traditionally, patients with less than 10% BSA involvementespecially Pediatric Scaling Diseases: An Approach to Pediatric Psoriasis Next Steps in Dermatology Too often, BPC 157 gets boxed into a single use: injury recovery. Gabriel Alizaidy, MD, MS Apremilast in the therapy of moderate to severe chronic plaque psorias DDDT Dove Medical Press Experiences with peptides BPC 157 and TB 500? Signaling pathways and targeted therapies for psoriasis Signal Transduction and Targeted Therapy